ストックスクリーナーアプリを入手
17.59
5.96%
0.99
アフターアワーズ：
17.59
前日終値:
$16.60
開ける：
$16.01
24時間の取引高:
3.46M
Relative Volume:
8.35
時価総額：
$957.17M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.51%
1か月 パフォーマンス:
-4.30%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$16.01
$18.08
1週間の範囲:
$16.01
$18.77
52週間の値動き範囲:
$16.01
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
BCAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
17.59 | 957.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
| 2024-10-08 | 開始されました | Stifel | Buy |
| 2024-10-08 | 開始されました | TD Cowen | Buy |
すべてを表示
Bicara Therapeutics Inc (BCAX) 最新ニュース
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownShould You Sell? - MarketBeat
This cancer drug developer held the Bay State's largest IPO of 2024 - The Business Journals
Bicara Therapeutics (NASDAQ:BCAX) Reaches New 12-Month LowShould You Sell? - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 5.8%Time to Sell? - MarketBeat
The Manufacturers Life Insurance Company Takes $582,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year LowShould You Sell? - MarketBeat
763,943 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Wellington Management Group LLP - MarketBeat
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Point72 Asset Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Now Covered by HC Wainwright - MarketBeat
Janus Henderson Group PLC Buys New Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
31,780 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Walleye Capital LLC - MarketBeat
2,273,792 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Fmr LLC - MarketBeat
HC Wainwright & Co. Initiates Coverage of Bicara Therapeutics (BCAX) with Buy Recommendation - MSN
Maven Securities LTD Buys Shares of 50,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
35,000 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Samsara BioCapital LLC - MarketBeat
RA Capital Management L.P. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Point72 DIFC Ltd Takes $1.42 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Baker BROS. Advisors LP Makes New $21.23 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Braidwell LP Makes New $42.22 Million Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Vestal Point Capital LP Acquires Shares of 425,000 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat
Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks
Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com
Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat
Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa
Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com
Bicara shares initiated with Buy on cancer drug potential - Investing.com India
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa
Bicara Therapeutics Inc (BCAX) 財務データ
Bicara Therapeutics Inc (BCAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Bicara Therapeutics Inc (BCAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Flynn James E | Possible Members of 10% Group |
Sep 17 '24 |
Buy |
18.00 |
70,000 |
1,260,000 |
897,587 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):